授权收入+新增品种有望带来业绩增量，八大平台彰显研发实力石药集团是一家集研发、生产和销售于一体创新制药企业，成药业务为第一大业务，近年来受核心产品恩必普医保价格调整及集采影响业绩短期承压。2025Q1，公司实现收入70.15 亿元，同比下降21.9%；归母净利润为14.95 亿元，同比下降8.3%；其中成药业务收入同比下降27.3%，但其中新增授权收入达7.18 亿元，显著缓冲了集采与医保政策带来...
Source Link授权收入+新增品种有望带来业绩增量，八大平台彰显研发实力石药集团是一家集研发、生产和销售于一体创新制药企业，成药业务为第一大业务，近年来受核心产品恩必普医保价格调整及集采影响业绩短期承压。2025Q1，公司实现收入70.15 亿元，同比下降21.9%；归母净利润为14.95 亿元，同比下降8.3%；其中成药业务收入同比下降27.3%，但其中新增授权收入达7.18 亿元，显著缓冲了集采与医保政策带来...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.